0001415889-24-009272.txt : 20240327 0001415889-24-009272.hdr.sgml : 20240327 20240327200016 ACCESSION NUMBER: 0001415889-24-009272 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240325 FILED AS OF DATE: 20240327 DATE AS OF CHANGE: 20240327 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Teehan Brendan CENTRAL INDEX KEY: 0001891900 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 24792931 MAIL ADDRESS: STREET 1: C/O ACADIA PHARMACEUTICALS INC. STREET 2: 12830 EL CAMINO REAL, SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 form4-03272024_110355.xml X0508 4 2024-03-25 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001891900 Teehan Brendan C/O ACADIA PHARMACEUTICALS INC. 12830 EL CAMINO REAL, SUITE 400 SAN DIEGO CA 92130 false true false false EVP, COO, HEAD OF COMMERCIAL 0 Common Stock 2024-03-25 4 A 0 10048 0 A 41480 D Common Stock 2024-03-27 4 S 0 5140 17.90 D 36340 D Stock Options (Right to Buy) 17.84 2024-03-25 4 A 0 89516 0 A 2034-03-24 Common Stock 89516 89516 D Restricted Stock Units 2024-03-25 4 A 0 27460 0 A Common Stock 27460 27460 D Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at 50% of target. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). 25% of the shares subject to the Stock Option will vest and become exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in four equal annual installments beginning March 25, 2025. /s/ Jennifer J. Rhodes, Attorney-in-Fact 2024-03-27